![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/13/2898636/0/en/Ocular-Therapeutix-Highlights-Exceptional-AXPAXLI-SOL-1-Enrollment-and-Plans-for-Repeat-Dosing-Study-SOL-R-in-wet-AMD-at-Investor-Day-Along-with-Positive-48-week-Data-from-HELIOS-N.html
https://www.globenewswire.com/news-release/2024/06/05/2893760/0/en/Ocular-Therapeutix-to-Host-Investor-Day-on-June-13-2024.html
https://www.globenewswire.com/news-release/2024/06/04/2893431/0/en/Ocular-Therapeutix-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/07/2876266/0/en/Ocular-Therapeutix-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/06/2875710/0/en/Ocular-Therapeutix-to-Present-at-Two-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/07/2877203/0/en/Ocular-Therapeutix-Reports-First-Quarter-2024-Results.html
https://www.globenewswire.com/news-release/2024/05/03/2875044/0/en/Ocular-Therapeutix-To-Present-at-Two-Ophthalmology-Meetings-May-4-9-2024.html
https://www.globenewswire.com/news-release/2024/05/01/2873130/0/en/Ocular-Therapeutix-to-Host-Investor-Day-in-New-York-City-on-Thursday-June-13-2024.html
https://www.globenewswire.com/news-release/2024/04/18/2865250/0/en/Ocular-Therapeutix-Announces-Positive-Topline-Phase-1-Data-for-AXPAXLI-in-Diabetic-Retinopathy.html
https://www.globenewswire.com/news-release/2024/04/16/2863461/0/en/Ocular-Therapeutix-Strengthens-Clinical-Team-with-Appointment-of-Key-Retinal-Leaders.html